Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block may help septic Patients' organs recover

NCT ID NCT05623722

Disease control Sponsor: Jing Cai, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a nerve block (erector spinae plane block) can improve organ function in septic patients who also have acute gut injury. The block uses a numbing medicine (ropivacaine) delivered near the spine. Researchers will measure organ failure scores in 116 ICU adults over 7 days. If successful, it could become a supportive therapy for sepsis-related organ damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ropivacaine (a numbing medicine) given as a nerve block
What this could lead to
If it works, this could offer a new way to help septic patients with gut injury recover organ function faster in the ICU.
What could go wrong
This is a small, early-stage trial (116 people) and the nerve block is an add-on to standard care. The results may not apply to all sepsis patients, and there are risks like bleeding or infection from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Septic patients with acute gastrointestinal injury grade II or III; * Age over 18 years; * Expected to stay in the ICU for at least 3 days or longer; Exclusion Criteria: * Mean arterial pressure less than 65 mmHg after fluid resuscitation, or requirement for an intravenous norepinephrine dose of greater than 0.5 µg/kg/min to maintain a normal mean arterial pressure; * Heart rates less than 50 beats/min, or concomitant with moderate-to-severe atrioventricular block without a pacemaker; * Contraindications for erector spinae plane blocks, including infection of the puncture site, spinal diseases or immobilization; * Primary gastrointestinal disorders requiring a surgical procedure, such as mechanical intestinal obstruction, massive gastrointestinal hemorrhage, and gastrointestinal perforation; * Gastrointestinal operation within one week before enrollment; * Neuromuscular disorders; * Coagulation abnormalities：activated prothrombin time or prothrombin time is prolonged with 2 folds, or platelet count less than 50×109/L; * End-stage malignant tumor or cachexia; * History of allergy to amide anesthetics; * Known pregnancy;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute gastrointestinal injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis multiple organ dysfunction syndrome Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute gastrointestinal injury Organ dysfunction syndrome Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Intensive Care Medicine of Zhujiang Hospital,Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510282, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.